A Single-center Study Designed to Evaluate the Safety and Efficacy of Tulipon
Withdrawn
- Conditions
- Safety Issues
- Registration Number
- NCT04268758
- Lead Sponsor
- Hadassah Medical Organization
- Brief Summary
Subjects who normally use tampons will use Tulipon device during one menstrual cycle. Baseline and post usage clinical evaluation will be performed for safety testing.
- Detailed Description
Subjects use Tulipon device during one menstrual cycle. Baseline and post usage clinical evaluation will be performed for safety testing.
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- Female
- Target Recruitment
- Not specified
Inclusion Criteria
- Women aged 18-45 years
- Regular menstrual cycles (21-35 days)
- Uses tampons every month for the last 2 months to handle their monthly bleeding.
- Active Bleeding lasts at least 3 days
- Willing not to change their feminine care or hygiene practices during their participation in the study (except as directed by the protocol and instructions for participants)
- Non-pregnant, with no intentions to get pregnant during the clinical trial
- Willing to use pads provided thought the study only for the duration of this study
- Subject is able to comply with all the requirements of the study and agrees to participate in all the activities of the study
- Signed written informed consent form (ICF) to participate in the study
Exclusion Criteria
- Pregnant or lactating women
- Gave birth less than a 12 month prior to the study.
- Virgin
- Using medications to manage pain during active bleeding
- Using intrauterine device or intrauterine device with hormones (Mirena)
- Had experienced Toxic shock syndrome (TSS)
- Previous diagnosis of primary or secondary dysmenorrhea
- Previous diagnosis of endometriosis
- Experiences urinary incontinence
- Suffers from uterus or urine prolapse
- Abnormal findings following the gynecological exam
- Subjects with a known or suspected sensitivity to any of the device materials (Polyethylene, Polyurethane, Nylon, Cotton)
- Been through a vaginal operation in the last 6 months prior to the study.
- Participation in current or recent clinical trial within 30 days prior to baseline visit
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method safety and efficacy of the Tulipon. 1 month We will take vaginal cultures to show no vaginal infection. By questionnaire we will find out about leakage of period blood from the Tulipon.
- Secondary Outcome Measures
Name Time Method